(ANRO) Alto Neuroscience - Ratings and Ratios

Alto Neuroscience, Inc. (NYSE:ANRO) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for mental health disorders. Its pipeline includes ALTO-100, currently in Phase 2b trials for major depressive disorder (MDD) and Phase 2a for post-traumatic stress disorder (PTSD). ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist, is in Phase 2b trials for MDD. The company also develops ALTO-101, a novel phosphodiesterase 4 inhibitor in Phase 1 for cognitive impairment in schizophrenia, and ALTO-203, a histamine H3 receptor inverse agonist in Phase 1 for MDD with high anhedonia. Additionally, ALTO-202, an NMDA receptor GluN2B subunit antagonist, is in Phase 1 for MDD. Alto Neuroscience also focuses on pharmacodynamically synergistic combinations and a biomarker platform to identify patient-specific treatment responses. Founded in 2019, the company is based in Los Altos, California.

From a technical standpoint, ANROs stock shows a declining trend, with SMA20 at 3.25, SMA50 at 3.90, and SMA200 at 8.47, indicating long-term downward momentum. Average volume of 410,875 shares suggests moderate liquidity, with an ATR of 0.31 reflecting limited price volatility. The stock last traded at 3.38.

Fundamentally, Alto Neuroscience has a market cap of $86.03M, with a P/B ratio of 0.51, indicating undervaluation relative to book value. The company reports a return on equity (RoE) of -34.81%, reflecting ongoing losses typical of early-stage biotech firms. With no P/E or P/S ratios due to lack of earnings or sales, the stock is speculative, driven by clinical trial outcomes and pipeline progression.